H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers.

GENT, Belgium & MALVERN, Pa. & TOKYO, June 04, 2025--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the ...

The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2. Already widely available ...

The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2.

Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

After decades of research, the U.S. Food and Drug Administration (FDA) has approved a test that can detect the buildup of ...

The Lumipulse test has specifically been approved to help diagnose the disease in the clinical setting. Dr. Amanada Smith said that makes it the first and only test with that advantage.

The Lumipulse test has specifically been approved to help diagnose the disease in the clinical setting. Dr. Amanada Smith said that makes it the first and only test with that advantage.

Down Syndrome, caused by an extra copy of chromosome 21, is one of the most common chromosomal disorders, marked by intellectual disability, developmental delays, and health issues like heart defects ...